Teclistamab Induced a Profound Hematologic Response in Light Chain Deposition Disease With Probable Cardiac Involvement.

Authors

Xinyi Xiong, Danqing Zhao, Jian Li, Kaini Shen

Published in

Hematological oncology. Volume 44. Issue 6. Pages e70278.

Abstract

We report the first case of using teclistamab, a BCMA × CD3 bispecific antibody, in a 63-year-old male with κ-light chain deposition disease (LCDD) involving the kidneys and probably the heart. The patient initially responded to daratumumab-pomalidomide-dexamethasone but experienced hematologic relapse. Salvage therapy with teclistamab induced a rapid and sustained hematologic complete response without cytokine release syndrome or neurotoxicity. Renal and cardiac functions remained stable. This case provides critical early evidence that BCMA-directed immunotherapy may serve as an effective salvage strategy for this rare plasma cell disorder, addressing a significant unmet therapeutic need.

PMID:
42894981
Bibliographic data and abstract were imported from PubMed on 19 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.